IFF flavor 316 282, Paracetamol, Pseudoephedrine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Upper Respiratory Infections

Conditions

Upper Respiratory Infections

Trial Timeline

May 1, 2012 → May 1, 2012

NCT ID

NCT01586962

About IFF flavor 316 282, Paracetamol, Pseudoephedrine

IFF flavor 316 282, Paracetamol, Pseudoephedrine is a phase 3 stage product being developed by Novartis for Upper Respiratory Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01586962. Target conditions include Upper Respiratory Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01586962	Phase 3	Completed	May 1, 2012	May 1, 2012	Upper Respiratory Infections

Competing Products

20 competing products in Upper Respiratory Infections

See all competitors

Product	Company	Stage	Hype Score
Nivolumab 100 MG in 10 ML Injection	Ono Pharmaceutical	Phase 2	52
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	85
ABBV-950 + BOTOX + Placebo for ABBV-950	AbbVie	Phase 1	33
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	52
BOTOX	AbbVie	Approved	85
MK-3475 and BCG	Merck	Phase 2	52
Montelukast + Placebo	Merck	Approved	85
Muntelukast + Placebo	Merck	Phase 3	77
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets	Novartis	Phase 3	77
diclofenac potassium + nimesulide	Novartis	Approved	85
Diclofenac gel	Novartis	Approved	85
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin	Novartis	Phase 3	77
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab	Gilead Sciences	Phase 3	76
Azithromycin SR	Pfizer	Phase 3	76
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
Nivolumab	Bristol Myers Squibb	Pre-clinical	22
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)	Regeneron Pharmaceuticals	Phase 2	51
IPN10200 + IPN10200 Placebo + Dysport	Ipsen	Phase 1/2	38
AboBoNT-A + OnaBoNT-A	Ipsen	Approved	82
Botulinum toxin type A	Ipsen	Phase 3	74

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved